Back to Top


Big Data and models for personalized Head and Neck Cancer Decision support

BD2Decide aims to develop a more precise prognostic prediction than the ones currently used in Cancers of Head and Neck Region (HNC), which targets to implement the first-line treatment in order to maximise the therapeutic results and minimise the impacts of HNC therapy. Currently, the adopted treatment decision method is based on prognostic systems, which consider only a few risk factors and result in late diagnosis of relevant cases in an advanced Stage.

BD2Decide introduces a Decision Support System (DSS), which provides clinicians with the "means" and all the necessary information to tailor treatment and care delivery pathway to each and any HNC patient during their usual practice, in contrast to current “one-size-fits-all approach”. This project, co-funded by the EU under the H2020-PHC-2015 program, realizes and validates an Integrated Decision Support System that links population-specific epidemiology and behavioral data, patient-specific genomic, pathology, clinical and imaging data with big data techniques, multi-scale prognostic models.

BD2Decide will improve the clinical decision process, uncover new patient-specific patterns that can improve care, and create a virtuous circle of learning. A multi-centric clinical study with more than 1.000 patients will be used to validate the system.

The BD2Decide Consortium is coordinated by Azienda Ospedaliero-Universitaria di Parma (Italy) and consists of Universidad Politecnica de Madrid (Spain), as the technical leader, Stichting Vu-Vumc (the Netherlands), Heinrich-Heineuniversitaet Duesseldorf Udus (Germany), Fondazione IRCCS Istituto Nazionale dei Tumori (Italy), Fraunhofer Gesellschaft Zur Forderung der Angewandten Forschung Ev (Germany), Athens Technology Center SA (Greece), ALL-IN-IMAGE LTD (Israel), Stichting Maastricht Radiation Oncology MAASTRO Clinic (the Netherlands), Politecnico di Milano (Italy), Multimed Engineers SRL (Italy) and Universita Degli Studi di Parma (Italy).

ATC is leading the development of advanced graphical visualization tools for prognostic data disclosure and patient co-participation to the selected treatment.

The project started in January 2016 and has a duration of 40 months.